Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab vs Physicians' Choice in Bulky Fludarabine-Refractory CLL
NCT01313689Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by Novartis. Started Apr 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01313689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313689.